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The p53 tumor suppressor is a key mediator of cellu-
lar responses to various stresses. Here, we show
that under conditions of basal physiologic and cell-
culture stress, p53 inhibits expression of the CD44
cell-surface molecule via binding to a noncanonical
p53-binding sequence in theCD44 promoter. This in-
teraction enables an untransformed cell to respond
to stress-induced, p53-dependent cytostatic and
apoptotic signals that would otherwise be blocked
by the actions of CD44. In the absence of p53 func-
tion, the resulting derepressed CD44 expression is
essential for the growth and tumor-initiating ability
of highly tumorigenic mammary epithelial cells. In
both tumorigenic and nontumorigenic cells, CD44’s
expression is positively regulated by p63, a pa-
ralogue of p53. Our data indicate that CD44 is a key
tumor-promoting agent in transformed tumor cells
lacking p53 function. They also suggest that the de-
repression of CD44 resulting from inactivation of
p53 can potentially aid the survival of immortalized,
premalignant cells.
INTRODUCTION
CD44 is a transmembrane cell-surface protein (Aruffo et al.,
1990) that is synthesized in multiple isoforms because of alterna-
tive splicing of its pre-mRNA. Although it lacks its own signaling
domain, it has recently been shown to be essential for the hom-
ing and stem cell properties of leukemic stem cells (Jin et al.,
2006; Krause et al., 2006). CD44 has also been found to support62 Cell 134, 62–73, July 11, 2008 ª2008 Elsevier Inc.anchorage-independent growth in vitro and tumor growth and
metastasis in experimental models of solid cancers (Barbour
et al., 2003; Weber et al., 2002; Yu et al., 1997), whereas it in-
hibited tumor growth in yet other models (Gao et al., 1997;
Schmits et al., 1997). The precise role played by CD44 in tumor-
igenesis has thus remained unclear.
The tumor-promoting functions of CD44 have been attributed
to its association with and costimulation of signaling by a number
of growth factor receptors, such as epidermal growth factor re-
ceptor-2 (Her2), epidermal growth factor receptor-1 (Her1), and
hepatocyte growth factor receptor (Met) (Ponta et al., 2003). In
the case of breast cancer pathogenesis, for example, the most
prominent of these receptors is Her2, which is overexpressed
in 20%–30% of these tumors and is responsible for releasing mi-
togenic and trophic signals into breast cancer cells (Yarden,
2001). These and other observations have suggested that
CD44 confers a decided growth advantage on certain types of
cancer cells. Moreover, the CD44 cell-surface antigen serves
as a useful marker for detecting and enriching for several types
of tumor-initiating cells (Al-Hajj et al., 2003; Dou et al., 2007;
Hurt et al., 2008; Wright et al., 2008; Yang et al., 2008), which
is consistent with its tumor-promoting capabilities cited above.
We hypothesized that signals regulating CD44 expression are
essential for understanding the role of this protein in tumorigen-
esis. In studying this issue, we noted that immunohistochemical
analyses of clinical samples of hepatocellular and renal carcino-
mas had demonstrated that CD44 protein is expressed at high
levels together with elevated levels of p53 (Endo and Terada,
2000; Zolota et al., 2002). Since the expression of p53 protein
in tumor samples indicates the presence of a mutant, functionally
inactive p53 protein (Iggo et al., 1990; Sjogren et al., 1996), this
suggested that CD44 might be repressed by wild-type p53.
In response to strong cellular stresses, such as DNA damage
or oncogenic signals, the wild-type form of p53 regulates
expression of a large cohort of genes that effect cell-cycle arrest,
senescence, and apoptosis (Levine, 1997; Levine et al., 2006).
Recent findings have uncovered additional roles of the p53 pro-
tein that is expressed under basal physiologic and cell-culture
stress conditions, notably regulation of mitochondrial respiration
(Bensaad et al., 2006; Matoba et al., 2006), autophagy (Crighton
et al., 2006), protection of the genome from reactive oxygen spe-
cies (Sablina et al., 2005), and inhibition of the self-renewal ca-
pacity of neuronal stem cells (Meletis et al., 2006; Piltti et al.,
2006). Under normal in vivo conditions, specifically in primary
mouse mammary epithelial cells, p53 regulates the expression
of 40 transcripts, pointing to its potentially important physio-
logic role in the absence of any unusual cell-physiologic stresses
(Aldaz et al., 2002).
The p53 paralogue, p63, has been recently shown to positively
regulate CD44 mRNA expression in microarray-based gene ex-
pression analyses of the MCF10A immortalized nontumorigenic
breast epithelial cell line. This study demonstrated that ectopic
expression of p63 leads to the upregulation of CD44 expression,
whereas shRNA directed against p63 mRNA leads to loss of
CD44 expression (Carroll et al., 2006). However, this work did
not indicate whether p63, which is essential for the normal devel-
opment of epithelial tissues (Mills et al., 1999; Yang et al., 1999),
is also able to positively regulate CD44 expression at the protein
level and in tumorigenic cells. These various observations pro-
voked us to examine the mechanisms regulating the abundance
of CD44 in cells and the functional consequences of its expres-
sion at various levels in such cells.
RESULTS
Repression of CD44 Expression by p53
To address the regulation and apparently important role of
CD44 in mammary epithelial cell physiology and tumorigenesis,
we chose to analyze its function in a novel type of early-
passage, human mammary epithelial cells (BPECs) that were
recently isolated and propagated in this laboratory (Ince et al.,
2007). The experimentally transformed derivatives of these
cells, termed BPLER cells, were created by the introduction of
genes encoding the hTERT telomerase subunit, the SV40 large
and small T antigens, and the H-Ras V12 oncoprotein (Hahn
et al., 1999; Ince et al., 2007). These BPLER cells yield tumor
xenografts that closely resemble, at the histopathological level,
invasive ductal adenocarcinomas, the most common type of
human breast cancer. In addition, injection of as few as 10–
100 of these transformed cells suffices to induce tumors in im-
munocompromised mouse hosts, even in the absence of prior
enrichment of tumor-initiating cells (Ince et al., 2007). This tu-
mor-initiating efficiency is comparable to that of CD44high/
CD24low cells that have been isolated directly from populations
of human breast cancer cells (Al-Hajj et al., 2003). This experi-
mental model of human breast pathogenesis allowed us to
study the function and expression of p53 and CD44 in both pri-
mary BPEC cells and in the derived, experimentally transformed
BPLER cells.
Prompted by the clinical evidence cited above (Endo and Ter-
ada, 2000; Zolota et al., 2002), we undertook to confirm that p53
mutant status is in fact associated with elevated CD44 expres-sion in a series of breast cancer specimens whose p53 mutant
status and gene expression profiles were known (Miller et al.,
2005). Since not all p53 mutations are equally detrimental to
p53 function, we chose to further sort these tumor specimens
according to the expression of a p53-induced gene, p21Waf1. Al-
though CD44 is positively and negatively regulated by a number
of distinct signals (Ponta et al., 2003), we were surprised that p53
mutant/p21-low-expression patterns in human tumors were, on
their own, able to predict high CD44 expression, doing so in
a statistically significant manner (Figure S1 available online).
This correlation suggested that p53 could act as a negative
regulator of CD44 expression in spontaneously arising human
tumors.
We therefore undertook to investigate whether p53 indeed
functions to repress CD44 expression in untransformed human
mammary epithelial cells. Because the BPEC cells mentioned
above have a limited life span in culture, they were initially im-
mortalized by introduction of a vector expressing the catalytic
subunit of human telomerase (hTERT), yielding BPEC-T cells.
To visualize the CD44 protein expression at the single-cell level,
we immunostained subconfluent monolayer cultures of these
BPEC-T cells. Curiously, the CD44 expression in control
BPEC-T cells was found to be elevated in the outer perimeters
of BPEC-T cell clusters, with a gradual decrease toward the
center of each cluster (Figure 1A).
In order to explore the possible connection of this behavior
with p53 function, we infected populations of BPEC-T cells
with a lentiviral construct encoding an shRNA that causes degra-
dation of p53 mRNA or, alternatively, with a retroviral construct
encoding the human papillomavirus E6 oncoprotein, which is
known to trigger degradation of the p53 protein. The expression
gradient described above was absent in cells expressing the
p53-shRNA construct or in cells in which the E6 oncoprotein
was deployed to degrade p53 (Figure 1A). In both cases, these
cells exhibited elevated levels of CD44 protein nearly uniformly,
regardless of the cells’ positions within a cluster (Figure 1A). This
suggested that the uneven expression of CD44 by control BPEC-
T cells was a reflection of p53 function. Control experiments in
BPEC-T cells treated with a genotoxic agent—doxorubicin—in-
dicated that the p53 gene and protein expressed in all cellular lo-
cations within these clusters were equally capable of responding
to genotoxic stress (Figure S2).
These findings suggested heterogeneous activation of p53
protein expression within the cell clusters of BPEC-T cells grow-
ing in monolayer culture. To test this possibility, we performed
double immunofluorescent staining for both p53 and CD44.
As anticipated, the control BPEC-T cells revealed largely mutu-
ally exclusive localizations of the two proteins (Figure 1B), con-
sistent with the notion of p53-dependent repression of CD44.
Further analysis of protein expression in these cells with immu-
noblotting revealed that CD44 expression was significantly
increased in the confluent cells in which p53 expression had
been suppressed by either the shRNA construct or E6 oncopro-
tein (Figure 1C). At present, the nature of the contextual signals
causing differential activation of p53 expression within the
BPEC-T cell clusters is obscure. Nonetheless, these results pro-
vided an initial indication that high CD44 expression is a signature
of relatively low p53 activity.Cell 134, 62–73, July 11, 2008 ª2008 Elsevier Inc. 63
To determine whether p53 regulates CD44 expression at the
transcriptional or posttranscriptional level, we measured total
CD44 mRNA expression by semiquantitative RT-PCR using
primers to the CD44 sequences common to all CD44 mRNA iso-
forms. As shown in Figure 1D, the mRNA levels for CD44 paral-
leled the results from the protein expression analyses—i.e.,
CD44 mRNAs were upregulated 4- to 5-fold and CD44 protein
4-fold in BPEC-T cells in which p53 function had been largely
abolished. Hence, CD44 expression was suppressed by p53
largely through effects on CD44 mRNA levels.
We also examined how the levels of p53 expression were cor-
related with those of CD44 in a living tissue. To do so, we under-
took immunohistochemical analyses of the mammary glands of
10-week-old wild-type and p53/ isogenic mice. These analy-
ses demonstrated significantly higher CD44 protein expression
in the mammary glands of p53/ mice than in those of wild-
Figure 1. CD44 Expression in BPEC-T Cells
and Mammary Fat Pad Is Dependent on p53
(A) Immunofluorescent detection of CD44 and nu-
clei (DAPI) in BPEC-T cells stably infected with the
control shRNA against firefly luciferase (shLuc),
p53 shRNA (shP53), E6 oncoprotein-, or GFP-
expressing constructs in subconfluent cultures.
(B) Immunofluorescent analysis of CD44 and p53
protein coexpression in BPEC-T cells.
(C and D) Western blotting analysis of total CD44
protein (C) and semiquantitative RT-PCR analysis
of total CD44 mRNA expression (D) in confluent
BPEC-T cells with normal and inhibited p53 ex-
pression. The cDNAs were PCR amplified from
3.3 and 1.1 ng of cDNA.
(E) Immunohistochemical analysis of CD44 ex-
pression in mammary fat pads. The epithelial and
nonepithelial compartments of mammary glands
from p53/ or p53+/+ Balb/c mice were immuno-
stained for the epitope present in all known CD44
isoforms by the IM7 antibody and counterstained
with hematoxylin.
type animals. The difference in CD44 sig-
nal was most prominent in the basal
epithelial cells, but was also apparent
in occasional luminal epithelial cells
(Figure 1E).
To exclude the possibility that the ob-
served repression was a consequence
of genomic instability in these p53/
mice, we took advantage of a recently
published conditional mouse model, in
which p53 expression is restored in oth-
erwise p53 null tissues of mice by admin-
istration of tamoxifen to activate the Cre
recombinase (Ventura et al., 2007).
When p53 expression was restored in
the tissues of adult mice (with 50%–
80% efficiency in mammary epithelial
cells), we observed downregulation of
CD44 protein levels specifically in the
mammary epithelium of these mice but
not in the mammary epithelium of mice treated only with oil vehi-
cle (Figure S3). As before, these observations indicated that the
expression of p53 varied inversely with that of CD44. Moreover,
they indicated that p53 antagonism of CD44 expression can
operate in normal tissues, where p53 is expressed at low levels
and in the apparent absence of any unusual cell-physiologic
stresses.
Mechanism of CD44 Repression by p53
In order to explore the possibly direct influence of p53 on the pro-
moter of the CD44 gene, a 2 kb DNA segment located upstream
of its transcription initiation site was introduced into a luciferase
reporter vector. Since p53 can regulate transcription either
directly by binding to a promoter sequence or indirectly via pro-
tein-protein interactions (Ho and Benchimol, 2003), we distin-
guished between these alternative mechanisms by using two64 Cell 134, 62–73, July 11, 2008 ª2008 Elsevier Inc.
p53 mutants that are defective in DNA binding. As shown
in Figure 2A, in contrast to their wild-type counterpart, which
strongly repressed the activity of the CD44 promoter reporter
construct, both p53 mutants failed to do so. Hence, the actions
of p53 on theCD44 gene promoter appeared to require the intact
DNA-binding activity of p53.
Figure 2. Mechanism of p53-Mediated Repression of CD44
(A) Repression ofCD44 promoter activity with p53 in the human osteosarcoma
cell line SAOS-2 lacking endogenous p53 expression. Human CD44 promoter
(CD44P, 0–2021 bp upstream of translation-initiation codon) was fused to
a firefly luciferase gene in pGL3 vector. The CD44P construct was cotrans-
fected with CMV-vector-based constructs bearing either normal or specific-
DNA-binding-defective p53 genes into the SAOS-2 cells. The cells were lysed
30 hr after transfection and analyzed for luciferase activity (mean ± SD, n = 4).
(B) The consensus sequence of p53-mediated transcriptional regulation (up-
per sequence), a potential noncanonical p53-binding site in the CD44 pro-
moter, 239–263 bp upstream from the first transcription-initiation site (lower
sequence), and the introduced point mutations (in red, lower sequence)
used to inactivate the potential p53-binding site.
(C) Promoter reporter assay with normal CD44 promoter or mutated CD44P-
M1 constructs in SAOS-2 cells cotransfected with or without the p53 expres-
sion vector (mean ± SD, n = 4). The basal activity of promotorless construct
was subtracted from the presented values of CD44 promoter activity.
(D) Gel-shift analysis of p53 protein interaction with CD44P-derived, 32P-
labeled oligonucleotides with normal or mutated p53-binding site.
(E) Competition analysis of p53 protein interaction between labeled CD44P-
derived oligonucleotide and nonlabeled oligonucleotides bearing either normal
or mutated p53-binding site sequence.It remained unclear, however, whether the observed repres-
sion was mediated by direct binding of p53 to the CD44 pro-
moter. To address this issue, we attempted to identify a p53-
response element in this promoter. Indeed, sequence analyses
revealed a region within the CD44 promoter that exhibits strong
sequence similarity to the noncanonical p53-binding site found
in the MDR1 gene (Figure 2B) (Johnson et al., 2001), which is
known to contain four p53-binding elements. The canonical
p53-binding site implicated in activation of transcription by p53
is comprised of two copies of the sequence PuPuPuC(A/T) ar-
ranged head to head and separated by 0–13 nucleotides, as is
seen, for example, in the promoter of the p21Waf1 gene. The non-
canonical p53-binding site in the MDR1 gene consists of four
p53-binding sites that are oriented in an alternating head-to-
tail arrangement (Johnson et al., 2001). Accordingly, we created
a mutant CD44 reporter construct bearing three point mutations
in two of the four putative p53-response elements (Figure 2B). As
shown in Figure 2C, the resulting mutant CD44 promoter was no
longer repressed by ectopic expression of p53 in otherwise p53
null SAOS-2 osteosarcoma cells. In addition, in the absence of
ectopically expressed p53, the basal activity of the mutant pro-
moter was about 20% lower than that of the wild-type promoter,
suggesting the presence of some type of transcription-promot-
ing site within the p53-response elements (Figure 2C).
To prove that the CD44 reporter construct was also suscepti-
ble to p53-dependent repression when chromosomally inte-
grated, we introduced constructs encoding the wild-type CD44
promoter, the mutant CD44 promoter, or a promoterless re-
porter, each driving a luciferase gene, into lentiviral vectors
and used these to infect the BPEC-T cells with normal or exper-
imentally suppressed p53 levels. The promoter activities of the
resulting chromosomally integrated constructs closely paralleled
those obtained from transient transfections of SAOS-2 cells (Fig-
ures 2A and 2C) and suggested that the above-described nonca-
nonical p53-binding site is involved in repression of CD44
promoter activity in the presence of the basal p53 expression
in BPEC-T cells (Figure S4). These results agreed with deletion
analyses of the CD44 promoter performed in parallel (Figure S5).
In order to confirm the direct physical interaction of p53 with se-
quences in theCD44promoter,weextended thesestudies byper-
forming gel-shift analyses and chromatin immunoprecipitation.
Using DNA oligonucleotides mimicking the potential p53-binding
site, we demonstrated direct binding of p53 protein to the CD44
promoter sequence, as indicated by the retardation of electropho-
retic migration in the presence of added purified p53 (Figure 2D).
To analyze the specificity of this binding, we performed a compe-
tition assay with either an unlabeled wild-type oligonucleotide or
an oligonucleotide containing the base substitutionspreviously in-
troduced into the promoter in the promoter-reporter assays
described above. As shown in Figure 2E, the wild-type oligonucle-
otide was more efficient in displacing the labeled oligonucleotide
from the complex with p53 protein than was the mutated one.
In order to determine whether the interaction between CD44
promoter and p53 protein also occurs in vivo, we undertook
chromatin immunoprecipitation of chromatin complexes con-
taining p53 and analyzed them for the presence of a p53-
response site in CD44 promoter. As shown in Figure S6, we
were able to detect physical association of p53 with the CD44Cell 134, 62–73, July 11, 2008 ª2008 Elsevier Inc. 65
promoter sequence in BPEC-T cells. These results provide evi-
dence that p53 represses CD44 transcription via direct interac-
tion with a specific site within the CD44 promoter located at po-
sition 239 to 263 bp relative to the transcription start site of
the human CD44 gene (Shtivelman and Bishop, 1991).
CD44 Interferes with p53 Function in Immortalized
Nontumorigenic Cells
Having found that p53 functions as a repressor of CD44 expres-
sion, we attempted to discover the cell-physiologic rationale of
this repression. CD44 is known to act predominantly in
a growth-promoting and antiapoptotic fashion (Ponta et al.,
2003).Because the tumor-suppressing function ofp53 relies on in-
hibition of these processes, we hypothesized that p53 downregu-
lates CD44 expression in order to prevent CD44 from compromis-
ing its growth-inhibitory and proapoptotic functions.
Figure 3. Effect of CD44 Expression on
p53-Dependent Proliferation and Apoptosis
in BPEC-T Cells
(A) BPEC-T cells stably infected with retroviral vec-
tors expressing the standard form of CD44
(CD44s), control GFP, or lentiviral vectors express-
ing an shRNA directed against p53 (shp53) or con-
trol shRNA (shLuc) were analyzed for expression
levels of p53 and CD44 by western blotting. The
CD44 with higher Mw than CD44s is either a prod-
uct of differential posttranslational modification of
CD44s or an alternatively spliced variant form of
endogenous CD44, whose expression is upregu-
lated by ectopic expression of CD44s.
(B) Cell growth (mean ± SD, n = 3) of BPEC-T cells
variants in the presence or absence of EGF ana-
lyzed after 72 hr. The horizontal line represents
initial number of cells. Numbers on top of the col-
umns represent relativenumbers of cells in percent.
(C and D) Apoptosis (mean ± SD, n = 3) of cells
exposed to doxorubicin in the presence of EGF
(0.6 ng/ml), analyzed by TUNEL assay after 24 hr.
At the biochemical level, CD44 is known
to stimulate EGF-induced signaling (Bour-
guignon et al., 1997; Ponta et al., 2003).
We therefore asked whether CD44 could
facilitate EGF signaling in the BPEC-T cells
used in our experiments and, if so, whether
such signaling influenced these cells’ re-
sponses to p53-directed inhibition of cell
proliferation and induction of apoptosis.
To address these questions, we analyzed
p53 function in theBPEC-Tcellsexpressing
normal levels of p53 (shLuc/GFP), in BPEC-
T cells overexpressing the ‘‘standard’’ form
of CD44 (which does not contain variable
exons [shLuc/CD44s]), and in BPEC-T cells
expressing an shRNA directed against p53
(shp53/GFP; Figure 3A). The first of these
cells served as controls, since they were
forced to express GFP and an shRNA
directed against luciferase.
We exposed these various BPEC-T populations to chemically
defined serum- and growth-factor-free media with or without
added EGF. In the absence of added EGF, these three cell popu-
lations (shLuc/GFP, shLuc/CD44s, and shp53/GFP) were largely
quiescent. The presence of added EGF stimulated proliferation of
shp53 cells (5.9-fold relative to the control) and shLuc/CD44s
cells (6.1-fold relative to the control) but not the control shLuc/
GFP cells expressing basal p53 levels. Hence, the basal levels
of p53 present in the control cells sufficed to inhibit EGF-stimu-
lated proliferation. Moreover, the ectopic constitutive expression
of the standard form of CD44 in cells with basal levels of p53 in-
creased their EGF-stimulated proliferation rate to a level compa-
rable to that of cells in which p53 expression had been knocked
down: This similarity in proliferation rate correlated with compara-
ble expression levels of CD44 protein between these two cell lines
(Figure 3A). We concluded that any growth-inhibitory effects that66 Cell 134, 62–73, July 11, 2008 ª2008 Elsevier Inc.
p53 imposed on EGF-stimulated cell proliferation could be re-
versed by ectopic CD44s expression (Figure 3B).
To analyze effects of CD44 on p53-dependent apoptosis, we
challenged the various BPEC-T derivatives with the genotoxic
drug doxorubicin. Many of the cells expressing wild-type p53 re-
sponded to genotoxic stress by entering into apoptosis (19.5%
apoptotic, Figures 3C and 3D), whereas cells expressing the
p53 shRNA construct were largely protected from this fate
(2.3% apoptotic). Moreover, cell populations with wild-type p53
plus ectopically expressed CD44s were significantly more resis-
tant to doxorubicin-induced apoptosis (3.9% apoptotic) than
were cells expressing only endogenous levels of CD44. Lastly,
in doxorubicin-treated BPEC-T cell clusters growing in mono-
layer culture, the apoptotic cells were recruited from those that
expressed low levels of CD44 and high levels of p53 and were
localized to the interior of each cluster; this provided further
support for the notion that cells with high p53 expression are
more susceptible to apoptosis (Figure S7). We note that the
Figure 4. Effect of Inhibition of CD44 Ex-
pression on Proliferation, Apoptosis, and
EGF-Dependent Signaling in BPEC-T Cells
with Inhibited p53 Levels
(A) Western blotting analysis of CD44 and p53 in
cytokine-starved cells cultured in the presence or
absence or EGF for 24 hr.
(B) Cell growth (mean ± SD n = 3) of BPEC-T cells
stably infected with lentiviral constructs expressing
shRNA against CD44 or p53 was analyzed after
72 hr incubation in the presence or absence of EGF.
(C and D) Apoptosis (mean ± SD, n = 3) of BPEC-T
cells exposed to doxorubicin in the presence
of 1.2 ng/ml EGF, analyzed by TUNEL assay after
24 hr.
inhibition of apoptosis by CD44 was
paralleled by increased signaling by the
antiapoptotic PI3-kinase pathway in
both shLuc/CD44s and shp53/GFP cells,
as evidenced by higher levels of phos-
pho-Akt (Figure S8). In sum, these prolif-
eration and apoptotic assays provided
a clear functional rationale of the p53-
CD44 interaction: p53 must repress
CD44 expression in order to reduce the
antiapoptotic and mitogenic effects of
CD44.
CD44 Is an Effector of Growth-
Supporting and Antiapoptotic
Effects of Low p53 Expression
The experiments described above pro-
vided evidence that CD44 can counteract
p53 functions. However, it was unclear
whether the various responses to down-
regulated p53 expression could be attrib-
uted solely to the actions of the dere-
pressed CD44 observed in, for example,
the shp53/GFP BPEC-T cells (Figure 3).
To address this issue, we inhibited CD44 expression in shp53
BPEC-T cells by an shRNA construct that was designed to tar-
get the expression of all known CD44 isoforms (Ponta et al.,
2003). As a consequence, these shp53/shCD44-2 cells grew
more slowly (93% decrease) and had a more than 4-fold higher
apoptotic index than their shp53 counterparts (Figure 4). In this
respect, they resembled control cells with normal p53 levels and
p53-repressed CD44 expression. Hence, the antiapoptotic
effects deriving from suppression of p53 synthesis largely dis-
appeared if CD44 expression was also blocked. This indicates
that CD44 is a key effector of antiapoptotic and mitogenic
signals of shp53 cells. We also note that the shp53/shCD44-2
cells were more apoptotic than the cells with normal p53
expression, suggesting that the antiapoptotic functions of
CD44 extend beyond its ability to antagonize the proapoptotic
function of p53.
On the other hand, suppression of CD44 expression in cells
with normal p53 expression did not sensitize them toCell 134, 62–73, July 11, 2008 ª2008 Elsevier Inc. 67
doxorubicin-induced apoptosis to the same extent as it sensi-
tized the shp53 cells (Figure S9).
The Role of Standard Part of CD44 in CD44
Protein Functions
CD44 has multiple isoforms arising from alternative splicing of its
mRNA (Ponta et al., 2003). However, in the experiments de-
scribed here, the CD44 standard form (CD44s), whose se-
quences are present in all known CD44 isoforms, was found to
suffice to inhibit p53-dependent apoptosis and proliferation. To
address whether or not a CD44 isoform encoded by mRNAs
containing additional variable exons is also able to inhibit p53-
dependent functions more or less effectively than CD44s, we
transiently transfected the SAOS-2 cells with vectors expressing
either the CD44s or CD44VE isoforms together with apoptosis-
inducing amounts of p53 (Figures S10A and S10B). The mRNA
encoding CD44VE isoform contains eight out of the ten variable
CD44 exons (v3–v10). We found that both CD44s and CD44VE
isoforms inhibited p53-dependent apoptosis to approximately
the same extent (Figure S10C), indicating that inclusion of se-
quences encoded by the variable exons v3–v10 does not sub-
stantially influence the antiapoptotic activity of CD44.
CD44 Function and Expression in Tumorigenic BPLER
Cells with Inactivated p53
The interactions described above shed light on the role of CD44
expression in untransformed BPEC-T cells possessing wild-type
p53 function. We wondered whether CD44 could also exert
similar functions in the transformed, tumorigenic derivatives of
BPEC-T cells, termed BPLER cells, in which p53 is inactivated
through sequestration by the SV40 large T antigen. To analyze
CD44 function in this tumor xenograft model, we first infected
BPLER cells with lentiviral constructs expressing shRNAs di-
rected against the mRNA encoding the standard form of CD44,
or as control, against the firefly luciferase gene. As indicated in
Figure 5A, introduction of CD44-specific shRNAs decreased
CD44 protein expression by more than 95%.
BPLER cells expressing these CD44 shRNAs formed fewer tu-
mors, and those that did appear were quite small (50 mg or less);
this contrasted with the size of large tumors (average weight 220
mg) formed by the BPLER cells in which CD44 expression had
not been suppressed by the shRNA vector (Figures 5B and
5C). Significantly, immunoblotting analysis of those few tumors
that did emerge from cells infected with CD44-specific shRNA
constructs demonstrated that these tumors arose from the
minority of BPLER cells whose CD44 expression failed to be
suppressed by the shRNA (Figure 5D).
When analyzing tumor-initiating ability, another feature of tu-
mor cells, we found that it was substantially reduced in cells
with suppressed CD44 expression (56%–100% decrease, de-
pending on the numbers of implanted cells and on the particular
CD44 shRNA, Figure 5E) compared to their control counterparts.
This indicated that, in addition to serving as a useful marker for
breast tumor-initiating cells, CD44 positively regulates the func-
tions of these cells (Figure 5E). These results reinforced yet other
observations with an in vitro surrogate assay for tumorigenicity—
the soft agar colony-forming assay—which also demonstrated
that BPLER cells deprived of CD44 expression, unlike their con-68 Cell 134, 62–73, July 11, 2008 ª2008 Elsevier Inc.trol counterparts, failed to form anchorage-independent colo-
nies (Figures 5F and 5G). Our results, taken together with those
of others (Weber et al., 2002; Yu et al., 1997), demonstrate that
by fostering tumorigenic growth in the absence of functional
p53, CD44’s functions extend beyond antagonizing the proa-
poptotic and antiproliferative actions of p53.
CD44 Is an Effector of Enhanced Tumor Growth
in Tumor Cells with Low p53 Expression
The experiments described above provided evidence that CD44
contributes importantly to the tumor-initiating ability and tumor
growth of BPLER cells with suppressed p53 function. However,
it was unclear whether the suppression of p53 expression in can-
cer cells exhibiting wild-type, normal p53 expression would per-
mit increased CD44 expression and, if so, whether the resulting
elevating CD44 levels were important to any increases in tumor
growth observed after p53 suppression.
To address these questions, we examined cells of the A549
human lung adenocarcinoma line, which express wild-type
p53. In particular, we constructed A549 cell populations with ei-
ther suppressed p53 expression (shp53/shLuc) or suppressed
expression of both p53 and CD44 (shp53/shCD44-2 and
shp53/shCD44-3); as controls, we used cells expressing basal
levels of both p53 and CD44 proteins (shLuc). These cells were
first analyzed for their expression of p53 and CD44. As antici-
pated, cells with suppressed p53 expressed higher levels of
CD44 than did the control cells with normal p53 levels. In addi-
tion, both shRNA constructs directed against CD44 were able
to efficiently suppress CD44 protein expression (Figure 6A).
Upon injection into immunocompromised mice, A549 cells
with suppressed p53 gave rise to tumors that were two times
larger than tumors induced by control cells. However, the A549
cells with suppressed p53 and CD44 expression yielded tumors
3- to 4-fold smaller than those induced by cells that had only
suppressed p53 expression (Figure 6B). Taken together with ear-
lier results, these observations indicate that CD44 is an essential
effector of tumor growth caused by suppressed p53 expression
and that CD44 supports tumor growth through both p53-depen-
dent and p53-independent mechanisms.
Regulation of CD44 Expression by Proteins Related
to p53-Induced Signaling
In order to obtain a more detailed view of the possible roles of
other proteins in the p53 pathway that might modulate CD44 ex-
pression, we analyzed the potential involvement of the p21Waf1
protein and the p53 paralogue, p63. For example, p21 has
been reported to mediate certain types of p53-induced tran-
scription regulation (Gottifredi et al., 2001; Taylor et al., 2001).
In fact, knockdown of p21Waf1 expression, achieved by expres-
sion of two independent siRNAs to p21, did not influence CD44
protein levels in BPEC-T cells (Figure S11A), indicating that p21
is not an essential component of the p53-dependent repression
of CD44. Conversely, suppression of CD44 expression in BPEC-
T cells or its ectopic expression in MCF7Ras cells did not
influence the p21 levels in these cells (Figures S11B and S11C).
We also tested whether the p63,a p53 paralogue known tohave
partially overlapping promoter-binding specificities with p53 (Got-
tifredi et al., 2001), is essential for repression of CD44 expression.
As we discovered, shRNA-mediated knockout of p63 expression
did not result in activation but instead in inhibition of CD44 protein
expression in BPEC-T, as well as BPLER and lung adenocarci-
noma A549 cells (Figure 7A and Figures S12A and S12B). Hence,
p63 acts on the CD44 protein in a fashion opposite to that of p53
by stimulating CD44 expression, a finding that was also recently
reported by others (Boldrup et al., 2007; Carroll et al., 2006).
DISCUSSION
Inhibition of cell proliferation and induction of apoptosis and se-
nescence are thought to be the major biological outputs of the
p53 pathway in response to various types of cell-physiologic
stresses (Levine, 1997; Levine et al., 2006). We present evidence
revealing an additional mechanism of p53 action: Under condi-
Figure 5. Tumor Growth of Human Mam-
mary Epithelial BPLER Cells with Normal
and Suppressed CD44 Expression
BPLER cells were infected with a lentiviral vector
expressing an shRNA to firefly luciferase (shLuc)
or to CD44 (shCD44-2 and shCD44-3). The infec-
tion efficiency was more than 95% for all con-
structs (data not shown).
(A) The level of CD44 expression in individual in-
fected cell populations in vitro was analyzed by
western blotting 72 hr after the infection.
(B) Individual lentivirus-infected cells (106 cells per
injection) were injected in nude mice, and tumor
weights (mean ± SEM) were analyzed 4 weeks af-
ter the injection. Tumor incidence per injection is
indicated in parentheses.
(C) Hematoxylin and eosin staining of the resulting
tumors. The scale bar represents 500 mm.
(D) The level of CD44 expression in tumors arising
from individual infected cell populations was ana-
lyzed by western blotting 72 hr after the infection.
(E) Tumor-initiating frequency of individual in-
fected cell populations.
(F and G) Soft agar colony assay of individual len-
tivirus-infected cells. The cells (105 per 6 cm dish)
were plated in culture medium in soft agar and cul-
tured for 4 weeks. The assay was terminated when
colonies of control cells reached 1 mm in diameter,
at which point they were counted (mean ± SEM,
n = 3).
tions of minimal stress in vitro and in
vivo, the basal levels of p53 that are pres-
ent suffice to repress expression of CD44
mRNA. Several types of observations
persuade us that the cultured BPEC cells
studied here are experiencing very low
levels of cell-physiologic stress in the
chemically defined WIT medium. Under
these conditions of tissue culture, the
BPEC cells express minimal levels of
p53 over extended periods of time in
culture, significantly lower than the levels
expressed when human mammary epi-
thelial cells from reduction mammoplasties are propagated in
the MEGM medium that is commonly used for human mammary
epithelial cells (Ince et al., 2007). These low levels of p53 expres-
sion correlate with the ability of BPEC cells to proliferate for at
least 40 doublings in vitro (Ince et al., 2007). This notion that
p53 functions at basal levels in the absence of unusual stress
is further supported by our in vivo observation that CD44 expres-
sion is upregulated in the mammary fat pad of virgin p53/ mice
(relative to wild-type mice) that have not been exposed to any
stress beyond the stresses that attend normal development.
Taken together, these observations indicate that p53 exerts reg-
ulatory functions that are dissociated from its normal role in pro-
gramming responses to various types of cell-physiologic stress
and that p53 can do so when expressed at the low, basal levels
thatare usually depictedas its inactive, nonsignalingstate. Indeed,Cell 134, 62–73, July 11, 2008 ª2008 Elsevier Inc. 69
the recent report of p53’s ability to regulate the neuronal stem cell
pool (Meletis et al., 2006) is in consonance with this thinking.
The observations presented here suggest that high CD44 ex-
pression, by opposing p53 function, can serve as an important
growth-promoting and survival factor in early stages of tumor
progression, when its expression may counteract p53’s tumor-
suppressing functions. Acting in the opposite direction, p53
represses CD44 expression, doing so even when present at basal
levels and in the absence of any apparent cell-physiologic stress.
When placed in the context of previous reports, the present
observations suggest that p53 and CD44 mayestablish a self-am-
plifying positive feedback loop, in which p53 represses CD44
expression, which results in suppression of growth receptor sig-
naling and a resulting decrease in MDM2 activity, permitting, in
turn, further increases in p53 levels and function (Figure 7B) (Bour-
guignon et al., 1997; Mayo and Donner, 2001; Zhou et al., 2001).
Figure 6. Effect of Suppression of CD44 Expression on Tumor
Growth in A549 Cells with Suppressed p53 Levels
A549 cells were infected with a lentiviral vector expressing an shRNA to firefly
luciferase (shLuc), to p53 (shp53) or to CD44 (shCD44-2 and shCD44-3). The
infection efficiency was more than 95% for all constructs (data not shown).
(A) The level of p53 and CD44 expressions in individual infected cell popula-
tions in vitro was analyzed by Western blotting 72h after the infection.
(B) Individual lentivirus-infected cells (106 cells per injection) were injected in
nude mice and tumor weights (mean ± SEM) were analyzed 4 weeks after
the injection. Tumor incidence per injection is indicated in parentheses.70 Cell 134, 62–73, July 11, 2008 ª2008 Elsevier Inc.A variety of observations indicate that the CD44 molecule is an
important factor for the progression of acute myeloid leukemia (Jin
et al., 2006; Krause et al., 2006), as well as for the growth of both
primary and metastatic tumors (Ahrens et al., 2001; Yu et al.,
1997). We note that the CD44 in the presently described breast
Figure 7. Scheme of p53-CD44-p53 Axis in Untransformed and
Transformed Cells
(A) The p63 protein expression was inhibited by two independent shRNAs in
pLKO1-Puro lentiviral vector in BPEC-T cells. The cells were lysed and ana-
lyzed for p63 and CD44 protein expression by western blotting 1 week after in-
fection with viral shRNA constructs.
(B) The scheme of the function of p53-CD44-p53 axis in immortalized BPEC-T
cells. Unknown signals, dependent on a cell’s position within an epithelial cell
cluster, trigger induction of p53 expression, which leads, in turn, to CD44 re-
pression, slower proliferation, and increased apoptosis in response to a strong
genotoxic stress. Conversely, increased CD44 expression can inhibit p53 sta-
bility by stimulating Her2-dependent activation of MDM2 protein expression
(Mayo and Donner, 2001; Zhou et al., 2001).
(C) The summary of CD44 function in tumor cells. In highly tumorigenic BPLER
cells with SV40 LTg-inactivated p53, CD44 is essential for anchorage-inde-
pendent growth, tumor growth kinetics, and tumor-initiating ability. In A549
cells, suppression of p53 expression accelerates tumor growth, which is de-
pendent on elevated CD44 expression resulting from its derepression occur-
ring in the absence of p53. The expression of CD44 is positively regulated
by p63 in BPEC-T cells, in BPLER cells, and in A549 cells, but the detailed mo-
lecular mechanism of this regulation in not known.
tumor model is indispensable not only for tumor growth but also
for tumor-initiating ability, which correlates with its critical role in
fostering anchorage-independent growth (Figure 7C). Although
CD44 has been considered only as a marker of breast cancer
stem cells, the present observations indicate that it also contrib-
utes in functionally important ways to the maintenance of the
tumor-initiating ability of transformed cells (Al-Hajj et al., 2003).
In a fashion similar to its actions in untransformed breast epi-
thelial cells, p53 operating in lung carcinoma cells suppresses
CD44 protein expression, thereby precluding it from antagoniz-
ing p53 function. Most studies of p53 have suggested that the
loss of p53 function enables cancer cells to escape p53-induced
cytostasis and/or apoptosis that would otherwise be triggered
by the multiple cell-physiologic stresses encountered at various
stages of tumor formation. The present results indicate another
important benefit conferred on cancer cells by p53 loss—an in-
creased resistance to apoptosis and responsiveness to mito-
genic signals resulting from elevated CD44 levels.
In contrast to the ability of p53 to repress CD44 expression, its
paralogue, p63, acts in an opposing fashion to stimulate CD44
expression, as recently reported by others in the context of a hu-
man head-and-neck carcinoma cell line (Boldrup et al., 2007).
We note that suppression of p63 levels resulted in significant
loss of CD44 expression in BPEC-T cells, expressing primarily
the deltaN (DN) isoform of p63, in their tumorigenic BPLER deriv-
atives, and in human lung adenocarcinoma cells (Figure 7A and
Figures S12A–S12C). Hence, p63 stimulation of CD44 expres-
sion operates in multiple cell types and in both normal and trans-
formed cells. The mechanism of this activation by p63 and its
physiologic relevance require further investigation. Nonetheless,
it is already apparent that CD44 protein expression is positively
regulated by a transcription factor that is known to be essential
for normal epithelial development (Mills et al., 1999; Yang
et al., 1999) and for the proliferative potential of epithelial stem
cells (Senoo et al., 2007).
EXPERIMENTAL PROCEDURES
Plasmids and Constructs
The human CD44 promoter (2021 bp fragment upstream of translation initia-
tion site) was PCR amplified from chromosomal DNA of HMLE cells (Elenbaas
et al., 2001) with primers 50-AGCTCCTGAATCCATGCTGT-30 (forward) and 50-
CTTCGCAGACAGCTCACTTG-30 (reverse), reamplified with primers introduc-
ing NheI (50-ACTATGCTAGCCTGAATCCATGCTG-30) or XhoI (50-ATCAACTC
GAGGGTGTCCGGAGCGAA-30 ) restriction sites. The resulting fragment was
cloned into a pGL3 luciferase reporter vector (Promega), and sequence was
verified. The potential p53-binding site was mutated by QuickChange
site-directed mutagenesis kit (Stratagene), introducing the primer 50-
AGTGGGGCTCGGAGGTCCAGCCACCCCGCGACA-30, and the resulting
construct was verified by sequencing. The standard form of CD44 (CD44s)
was subcloned from CDM8 construct into retroviral vector pWZL-blasticidin.
Antibodies
For immunohistochemistry, we used CD44 antibody (Becton Dickinson, IM7).
For immunofluorecent detection, we used phycoerythrin (PE)-conjugated
CD44 antibody (Becton Dickinson, Nr.550989). For western blotting, we
used CD44 antibody MEM-85 (from V.Horejsi) and anti-CD44H antibody
(R&D Systems). For p53 and p21 immunofluorescence and/or western blotting
analyses, we used rabbit anti-p53 antibody (Santa Cruz, FL-393) and mouse
monoclonal antibody to p21 (Santa Cruc, sc-817). For western blotting detec-
tion of anti-Akt and anti-P-Akt, we used antibodies from Cell Signaling.Cell Culture
HMEC-T cells were cultured in MEGM media with bovine pituitary extract.
BPEC-T and BPLER cells were cultured in chemically defined WIT media
(Ince et al., 2007). The human osteosarcoma cell line SAOS-2 (ATCC no.
HTB85) and lung adenocarcinoma A549 cells were maintained in DME medium
supplemented with 10% fetal calf serum, 100 units/ml penicillin, 100 mg/ml
streptomycin, and 2 mM L-glutamine at 37C in 5% CO2. For western blotting
analysis of CD44 and p53 expressions, the A549 cells were cultured in WIT
medium. For promoter reporter assays, the SAOS-2 cells were cultured in
WIT or DME medium.
Immunofluorescence
Culturedcells were fixed with100% methanol, blocked with 10%calf serum and
stained sequentially with primary rabbit antibody against either p53 or p21, incu-
bated with secondary antibodies conjugated to Alexa-488, and then incubated
with pan CD44 antibody directly conjugated to phycoerythrin (BD PharMingen).
Semiquantitative RT-PCR
Complementary DNA from BPEC-T cells was synthesized from 1 mg of total
RNA and diluted to 100 ml. The cDNA solution (0.25–0.06 ml) was amplified
with primers to the standard region of CD44 gene (50-CCACGTGGA
GAAAAATGGTC-30 from exon 2 and 50-CATTGGGCAGGTCTGTGAC-30 from
exon 3) and to the control GAPDH gene (50-ACCCAGAAGACTGTGGATGG-
30 and 50-TCTAGACGGCAGGTCAGGTC-30). The amplified products were
resolved by agarose gel electrophoresis.
Promoter Reporter Assay
SAOS-2 cells or HMEC-T cells were plated 12 hr prior to transfection in 48-well
plates (33104 cells) inculture medium.Cellswere transfectedwithFugene trans-
fection reagent (Roche) with 200 ng of reporter plasmid and/or 10 ng of p53 plas-
mid. Thirty hours after transfection, cell extracts were prepared, and luciferase
activity was determined according to the vendor’s instructions (Promega).
Gel Shift Assay
Gel shift assays were performed with 50 ng of recombinant human p53 (Cal-
biochem) in 20 ml of binding buffer (10 mM HEPES [pH 7.5], 5 mM NaCl2,
0.1 mM EDTA, 1 mM dithiothreitol, and 20% glycerol). When indicated, cold
competitor or antibody was added in the concentrations noted. Reactions were
incubated at room temperature for 20 min prior to the addition of 0.2 ng of
double-stranded oligonucleotides (6 3 104 cpm) and then incubated for
additional 20 min at room temperature. The antibodies used for supershift as-
says were pAb421 (epitope: aa 371–380) and sc-6243 (Santa Cruz). Reactions
were electrophoresed on a 4% nondenaturing polyacrylamide gel, which was
dried and exposed to film for 16 hr at –80C.
Soft Agar Assay
A layer of 0.6% agar noble in DME without serum was placed onto 6 cm dishes.
BPLER cells were then seeded in 0.3% top agar containing WIT medium atop
the first layer. Fresh top agar was added after 1.5 weeks, and colonies were
counted after 4 weeks.
Apoptotic Assay
BPEC-T cells, 80% confluent, were incubated 48 hr with the DNA-damaging
agent doxorubicin in cytokine-free M199/F12 (1:1) culture medium supple-
mented with 100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM L-gluta-
mine, and various concentrations of epidermal growth factor (EGF). Cells
were than analyzed by TdT-mediated dUTP nick end-labeling (TUNEL) assay
or by Hoechst-33342 dye.
Proliferation Assay
BPEC-T cells (53 104) were plated on 6-well plates in cytokine-free M199/F12
(1:1) culture medium supplemented with 100 units/ml penicillin, 100 mg/ml
streptomycin, 2 mM L-glutamine, and various concentrations of EGF. Cells
were allowed to proliferate for 3 days and counted.Cell 134, 62–73, July 11, 2008 ª2008 Elsevier Inc. 71
Tumorigenic Assays
Subcutaneous tumorigenicity assays were performed as described (Elenbaas
et al., 2001) with modification. Six- to 8-week-old immunocompromised athy-
mic nude mice (Ncr-Nu, Taconic) were irradiated with 400 rad 4 hr prior to in-
jection. Cells (106) were resuspended in 100 ml of culture medium, mixed with
Matrigel (Becton Dickinson), and injected with a 25 gauge needle into anaes-
thetized mice. Tumor size was measured every 3–4 days. The time of initial tu-
mor formation was defined as the time when the tumor had reached a diameter
of 3 mm. Mice were sacrificed when the tumors grew to 1 cm in diameter or
after 5 weeks of monitoring. Tumors were fixed in 10% formalin and paraffin
embedded for histological examination or minced and lysed in HEPES-buff-
ered saline containing 1% NP-40 detergent and protease inhibitor mix (Roche).
Statistical Analysis
Statistical significance was analyzed by Student’s t test and expressed as
p value.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, and twelve figures and can be found with this article online
at http://www.cell.com/cgi/content/full/134/1/62/DC1/.
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